Injectable-focused pharmaceutical company Gland Pharma has reported a strong start to FY27, with consolidated revenue from operations increasing 20% year-on-year to Rs. 1,800.3 crore in Q1 FY27, compared with Rs. 1,505.6 crore in the corresponding quarter last year.

EBITDA increased 34% year-on-year to Rs. 493 crore, while EBITDA margin improved to 27% from 24% in Q1 FY26. Adjusted EBITDA rose 37% to Rs. 510.2 crore, with adjusted EBITDA margin expanding to 28% from 25%.

Profit before tax increased 39% year-on-year to Rs. 435 crore, while profit after tax rose 47% to Rs. 317 crore from Rs. 215.5 crore in Q1 FY26. PAT margin improved to 18% from 14% in the year-ago quarter.

Srinivas Sadu, Executive Chairman, Gland Pharma, said, “Our strong start to FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B business model. Growth was driven by recent product launches from the CDMO portfolio and strong customer demand for our diversified product mix.”

The company’s CDMO business contributed 50% of total revenue, growing 20% year-on-year to Rs. 891.5 crore. The B2B business, including B2C revenue, also contributed 50% of revenue and grew 19% year-on-year to Rs. 908.8 crore.

The U.S. remained the largest market, with revenue rising 32% year-on-year to Rs. 981 crore. Europe revenue increased 20% to Rs. 395.4 crore, while India revenue grew 12% to Rs. 66.6 crore. Revenue from the rest of the world increased 2% to Rs. 303.9 crore. Revenue from Canada, Australia and New Zealand declined 28% to Rs. 53.4 crore.‘

Gland Pharma invested Rs. 77.2 crore in R&D during the quarter, equivalent to 4% of consolidated revenue, primarily towards complex product development and filings.